Compare Hims and Hers Health Inc (HIMS) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Morgan Stanley — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while Morgan Stanley trades at $190.02 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 44.9× Hims and Hers Health Inc's market cap, and Morgan Stanley pays a 2.45% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Morgan Stanley for 92 Days on average.
| HIMS | MS | |
|---|---|---|
Market Cap | $6.55B | $294.39B |
Volume | 14,842,814 | 5,836,423 |
Sector | Health | Financials |
52-Week High | $62.76 | $228.42 |
52-Week Low | $14.52 | $151.86 |
Typical Hold Time | 21 Days | 92 Days |
Enterprise Value | $7.25B | $660.04B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
Morgan Stanley (MS) trades at $187.41, down 1.21% on the day, with a bearish technical signal from moving averages. The company shows strong fundamental momentum, with revenue growing to $66.0 billion in 2025 and net income reaching $16.9 billion, alongside three consecutive quarterly EPS beats. Analysts maintain a bullish stance with a $229.25 consensus price target, citing growth in wealth management and AI financing.
The outlook is positive given earnings momentum and strategic growth areas, but risks include volatile cash flows from operations and rising debt-to-asset ratios. The stock offers potential upside to analyst targets if execution continues, though macroeconomic and capital markets volatility pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
